European Drug Delivery Technologies Market Report

European Drug Delivery Technologies Market Report

European Drug Delivery Technologies Market Report
Report code - SR3595 Delivery - 2 Weeks
European-Drug-Delivery-Technologies-Market Size, Share, Trend, Forecast, Competitive Analy See more...

Market Insights

“The European drug delivery technologies market size was US$115.021 billion in 2024 and is likely to grow at a CAGR of 5.6% in the long run to reach US$177.925 billion in 2032.”

Market Dynamics

Introduction

European drug delivery technologies have evolved significantly, driven by advancements in pharmaceutical innovation, biologics, and the demand for targeted, efficient, and patient-friendly drug administration methods. These technologies aim to optimize the absorption, distribution, and efficacy of medications by controlling the rate, time, and location of drug release.

Recent Market JVs and Acquisitions:

In the European drug delivery technologies market, companies are increasingly pursuing mergers, acquisitions, and strategic partnerships to remain competitive and drive innovation. This trend is fueled by growing demand for advanced drug delivery solutions, including connected devices, smart injectors, implantable systems, and digital monitoring platforms. Pharmaceutical manufacturers, medical device companies, and technology firms are collaborating to combine drug development expertise with digital health, IoT-enabled monitoring, and real-time patient adherence solutions, enabling improved therapeutic outcomes, enhanced safety, and greater patient convenience.

A considerable number of strategic alliances, including M&As, JVs, etc., have been performed over the past few years:

  • June 2024: Aptar Digital Health (USA) formed a joint venture with SHL Medical (Switzerland) to integrate digital health platforms with connected drug delivery solutions, enhancing self-injection therapy experiences.
  • December 2024: Novo Holdings (Denmark) completed the acquisition of Catalent (USA), strengthening its drug development and manufacturing capabilities in Europe.
  • New Product Development
  • Johnson & Johnson (Belgium/Europe operations) introduced a connected autoinjector platform that combines self-injection devices with digital monitoring tools to enhance compliance, safety, and real-time treatment tracking for patients.
  • 3M Company (USA/Europe operations) launched an advanced transdermal patch system with integrated sensors that monitor drug release and patient adherence, improving therapeutic outcomes and convenience.

Market Segments' Analysis

Segmentations

List of Sub-Segments

Segments with High-Growth Opportunity

Technologies-Type

Analysis

Oral(Controlled Release, Orodispersible Tablets and Taste Masking, Others),Pulmonary(Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers),Transdermal(Passive, Active),Injectable(Conventional Injection Devices, Self-Injection Devices, Others),Ocular(Eye Drops, Ointment and gel, Others),Nasal(Nasal Drops, Nasal Sprays, Nasal Inhalers, Others),Topical(Liquid Formulations, Semi-Solid Formulations, solid Formulations),Implantable(Drug Eluting Stents, Implantable Infusion Pumps, Intravitreal Implants, Brachytherapy Seeds, Contraceptive implants),transmucosal(Oral,Others)

The Injectable Drug Delivery segment is projected to experience the highest growth in the European drug delivery technologies market. This growth is attributed to several factors, including the increasing demand for biologics, the rise in chronic diseases requiring long-term treatment, and advancements in self-administration technologies such as wearable injectors and autoinjectors. Additionally, the growing prevalence of conditions like diabetes and obesity is driving the need for efficient and convenient drug delivery methods.

 

By Technology Type

“Injectable Drug Delivery is expected to dominate the market during the forecast period.”

Based on technology type, the market is divided into Oral, Pulmonary, Transdermal, Injectable, Ocular, Nasal, Topical, Implantable, and Transmucosal systems. Injectable drug delivery is projected to grow the fastest in the European Drug Delivery Technologies market due to several factors. The rising prevalence of chronic diseases such as diabetes, obesity, and autoimmune disorders is increasing demand for biologics and self-administered therapies. Additionally, advancements in wearable injectors, autoinjectors, and other self-injection devices are enhancing patient convenience, adherence, and safety. This has created a strong need for efficient, reliable, and patient-friendly delivery methods, while the integration of digital monitoring and connected devices further supports market growth.

Key Players

The market is moderately fragmented. Most of the major players adopted partnerships, new product launches, and joint ventures to gain in the European drug delivery technologies market. The following are the key players in the European drug delivery technologies market. Some of the major players provide a complete range of services.

Here is the list of the Top Players (Based on Dominance)

  • Johnson & Johnson
  • Baxter International
  • 3M Company
  • Becton Dickinson & Co.
  • Catalent Pharma Solutions
  • Alkermes
  • Endo Pharmaceuticals
  • Nektar Therapeutics
  • SkyePharma PLC
  • Aptalis Pharma
  • Ypsomed Holding AG
  • The Dow Chemical Company

Note: The above list does not necessarily include all the top players in the market.

Are you the leading player in this market? We would love to include your name. Please write to us at [email protected]

Report Features

This report provides market intelligence most comprehensively. The report structure has been kept so that it offers maximum business value. It provides critical insights into market dynamics and will enable strategic decision-making for existing market players as well as those willing to enter the market. The following are the key features of the report:

  • Market structure: Overview, industry life cycle analysis, supply chain analysis.
  • Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
  • Market trend and forecast analysis.
  • Market segment trend and forecast.
  • Competitive landscape and dynamics: Market share, Service portfolio, New Product Launches, etc.
  • COVID-19 impact and its recovery curve.
  • Attractive market segments and associated growth opportunities.
  • Emerging trends.
  • Strategic growth opportunities for the existing and new players.
  • Key success factors.

The European drug delivery technologies market is segmented into the following categories. 

European Drug Delivery Technologies Market by Technology Type

  • Oral (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Controlled Release
  • Orodispersible Tablets and Taste Masking
  • Others
  • Pulmonary (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Dry Powder Inhalers
  • Metered Dose Inhalers
  • Nebulizers
  • Transdermal (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Passive
  • Active
  • Injectable (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Conventional Injection Devices
  • Self-Injection Devices
  • Others
  • Ocular (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Eye Drops
  • Ointment and Gel
  • Others
  • Nasal (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Nasal Drops
  • Nasal sprays
  • Nasal Inhalers
  • Others
  • Topical (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Liquid Formulations
  • Semi-Solid Formulations
  • Solid Formulations
  • Implantable (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Drug-Eluting Stents
  • Implantable Infusion Pumps
  • Intravitreal Implants
  • Brachytherapy Seeds
  • Contraceptive implants
  • Transmucosal (Regional Analysis: North America, Europe, Asia-Pacific, and Rest of the World)
  • Oral
  • Others

Research Methodology

  • This strategic assessment report from Stratview Research provides a comprehensive analysis that reflects today’s European drug delivery technologies market realities and future market possibilities for the forecast period. 
  • The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market.
  • The vital data/information provided in the report can play a crucial role for market participants and investors in identifying the low-hanging fruit available in the market and formulating growth strategies to expedite their growth process.
  • This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.
  • More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data.
  • We conducted more than 15 detailed primary interviews with market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respected clients:

Company Profiling

  • Detailed profiling of additional market players (up to three players)
  • SWOT analysis of key players (up to three players)

Competitive Benchmarking

  • Benchmarking of key players on the following parameters: Service portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected]

The European Drug Delivery Technologies Market refers to the industry focused on developing and commercializing advanced systems and methods for administering pharmaceutical compounds in Europe. It encompasses technologies designed to improve the delivery, absorption, and efficacy of drugs, while enhancing patient convenience, compliance, and safety. These technologies include controlled-release formulations, transdermal patches, inhalation devices, implantable systems, and smart drug delivery platforms that integrate digital monitoring.

Injectable (Conventional Injection Devices, Self-Injection Devices, Others) – This segment offers the highest growth opportunity due to increasing demand for biologics, chronic disease management, and self-administered therapies that improve patient compliance and convenience.

The forecasted value for the market is expected to be US$177.925 billion in 2032.

Western Europe is expected to hold the largest market share in the European Drug Delivery Technologies Market. This is due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, high adoption of innovative drug delivery systems, and strong R&D capabilities in countries such as Germany, France, and the UK.

The European drug delivery technologies market is projected to grow at a CAGR of approximately 5.6% by 2032, fueled by advancements in digital and connected delivery systems, increasing emphasis on patient safety and adherence, and the rising demand for smart, self-administered drug delivery solutions

Key factors that are driving the market are as follows: • Rising demand for biologics and biosimilars requires advanced delivery systems. • Growing prevalence of chronic diseases driving need for sustained drug delivery. • Focus on patient compliance and convenience through user-friendly devices. Advancements in drug delivery technologies are enhancing therapeutic outcomes.

Some of the major players are Johnson & Johnson, Baxter International, 3M Company, Becton Dickinson & Co., Catalent Pharma Solutions, Alkermes, Endo Pharmaceuticals, Nektar Therapeutics, SkyePharma PLC, Aptalis Pharma, Ypsomed Holding AG, and The Dow Chemical Company